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Centrosome abnormalities are a typical hallmark of human cancers. However, the origin and dynamics of such abnormalities 
in human cancer are not known. In this study, we examined centrosomes in Barrett’s esophagus tumorigenesis, a well-
characterized multistep pathway of progression, from the premalignant condition to the metastatic disease. This human 
cancer model allows the study of sequential steps of progression within the same patient and has representative cell lines 
from all stages of disease. Remarkably, centrosome amplification was detected as early as the premalignant condition and 
was significantly expanded in dysplasia. It was then present throughout malignant transformation both in adenocarcinoma 
and metastasis. The early expansion of centrosome amplification correlated with and was dependent on loss of function 
of the tumor suppressor p53 both through loss of wild-type expression and hotspot mutations. Our work shows that 
centrosome amplification in human tumorigenesis can occur before transformation, being repressed by p53. These findings 
suggest centrosome amplification in humans can contribute to tumor initiation and progression.
Centrosome amplification arises before neoplasia 
and increases upon p53 loss in tumorigenesis
Carla A.M. Lopes1,2*, Marta Mesquita1,3*, Ana Isabel Cunha1, Joana Cardoso4, Sara Carapeta4, Cátia Laranjeira1, António E. Pinto1, 
José B. Pereira‑Leal4, António Dias‑Pereira1,3, Mónica Bettencourt‑Dias2**, and Paula Chaves1,3**
Introduction
The centrosome has key roles in microtubule organization, sig-
naling, polarity, and cell division—all processes deregulated in 
tumorigenesis. Each centrosome, composed of two centrioles 
and a pericentriolar protein matrix (PCM), duplicates once per 
cell cycle to ensure bipolar spindle assembly during cell division 
(Bornens, 2012; Godinho and Pellman, 2014). Centrosome number 
amplification can lead to aberrant mitotic spindles and associated 
cell death (Holland et al., 2012; Marthiens et al., 2013). However, 
cancer cells with centrosome amplification can often survive 
cell division while generating genomic instability (Ganem et al., 
2009; Silkworth et al., 2009). Moreover, centrosome amplifica-
tion can promote aneuploidy and invasiveness in cultured cells 
as well as promote and enhance tumorigenesis in mice (Godinho 
et al., 2014; Coelho et al., 2015; Serçin et al., 2016; Levine et al., 
2017). As centrosome amplification is found in human tumors 
(Chan, 2011) but not in normal cells, it is an appealing feature to 
explore for diagnosis, prognosis, and therapy.
Despite being a cancer hallmark, the timing, mechanisms, 
and impact of centrosome deregulation in human cancer are 
poorly understood (Godinho and Pellman, 2014). Moreover, 
whether the incidence of centrosome amplification changes 
through progression is not known. This partly stems from lack 
of studies surveying centrosomes at the single-cell level through 
tumorigenesis. Moreover, most studies score only PCM compo-
nents, which may not harbor centrioles and thus not represent 
bona-fide centrosomes (Chan, 2011; Godinho and Pellman, 2014). 
Understanding the dynamics of centrosome amplification is 
essential to decipher its role in cancer.
It is critical to examine centrosomes along cancer progres-
sion. Barrett’s esophagus (BE) is a premalignant condition in 
which the normal esophageal epithelium is replaced by a stom-
ach/intestine-like metaplastic lining as a result of chronic reflux 
(Spechler et al., 2011). Its malignant transformation is a multistep 
process from metaplasia (premalignant condition) to dysplasia 
(intraepithelial neoplasia), adenocarcinoma (invasive neoplasia), 
and metastasis (Fig. 1 A; Haggitt, 1994). Given the risk of devel-
oping cancer, BE patients are included in a surveillance program 
(Spechler et al., 2011; Fitzgerald et al., 2014), which allows the 
study of the intermediate step between normal tissue and tumor 
initiation. Despite the increasing incidence of esophageal ade-
nocarcinoma, only some BE patients will progress (0.1–0.3%/yr; 
Hvid-Jensen et al., 2011; Schouten et al., 2011). However, neo-
plasia resections allow the unique study of sequential stages of 
progression in each individual patient and thus the more specific 
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detection of consistent differences through progression (Ross-
Innes et al., 2015; Stachler et al., 2015).
In this study, we used BE to uncover when and how centro-
some amplification arises. We established a method to identify 
centrosomes at the single-cell level in clinical samples and found 
that centriole number abnormalities arise early in BE progres-
sion both in clinical samples and cell lines. Moreover, we found 
an increase in abnormalities in dysplasia, which were dependent 
on p53 loss of function. Our findings suggest centrosome ampli-
fication can arise early in human tumorigenesis, being normally 
repressed by p53.
Results and discussion
Centrosome amplification arises as early as the premalignant 
condition and increases in dysplasia
To determine when centrosome number abnormalities arise, we 
selected cohorts of patients that allowed us to examine all stages 
of disease. We therefore included metaplasia samples from biop-
sies of patients that did not progress (cohort 1) as well as samples 
from patients subjected to resection upon progression to dyspla-
sia (cohort 2) or adenocarcinoma (cohort 3; Fig. 1 A and Table S1). 
In these, we analyzed in each patient areas of metaplasia, dys-
plasia, and adenocarcinoma (cohort 2) along with areas of meta-
plasia, adenocarcinoma, and lymph node metastasis (cohort 3). 
As comparison standards for normal epithelial tissue, we exam-
ined samples of native esophagus (normal lining; Fig. 1 A) and 
ileum (Fig. S1 B).
We established a method to identify centrosomes at the sin-
gle-cell level in tissue samples by immunofluorescence (IF). To 
ensure centrosome scoring, we labeled its structural compo-
nents: the centrioles (with glutamylated tubulin) and the PCM 
(with pericentrin; Fig. 1 B). Thus, only centrioles surrounded by 
the PCM were scored. Moreover, the background of glutamylated 
tubulin staining was sufficient to define cell boundaries (Fig. S1 
A), thus allowing centriole number scoring cell by cell.
Centriole amplification was never observed in the normal lin-
ing of the esophagus (Fig. 1, B and C) or the ileum (Fig. S1, C and 
D). Although centriole amplification was also not detected in meta-
plasia from biopsies that had not progressed, cells with supernu-
merary centrioles were detected early in metaplasia adjacent to 
dysplasia or adenocarcinoma as well as in all subsequent steps of 
progression (Fig. 1, B and C; and Fig. S1, C–E). Moreover, the num-
ber of centrioles found per cell increased upon progression (Fig. S1 
D). Centriole amplification increased significantly from metapla-
sia to dysplasia (Figs. 1 C and S1 C). Our data also indicate a decrease 
in adenocarcinoma followed by an increase in metastasis (Figs. 1 C 
and S1 C). This change in incidence along progression suggests that 
the percentage of cells with centrosome amplification is dynamic. 
Our observations suggest that the impact of these abnormalities is 
likely context dependent, being differently tolerated and having 
different consequences along progression.
Loss of p53 function correlates with the increase in 
centrosome amplification
Mutations in p53, the most mutated gene in human cancers 
(Petitjean et al., 2007), define the boundary from metaplasia 
to dysplasia in BE progression (Weaver et al., 2014). As p53 loss 
is associated with centrosome amplification in many human 
tumors (Chan, 2011; Godinho and Pellman, 2014), we hypothe-
sized that p53 inactivation is responsible for the increased cen-
trosome amplification observed in dysplasia.
To test this, we sequenced p53 in metaplasia and dysplasia 
samples from the same patient (cohort 2). In agreement with 
previous studies (Hamelin et al., 1994; Gleeson et al., 1995, 
1998; Del Portillo et al., 2015), we found that p53 was mutated 
in dysplasia: all samples contained multiple mutations in high 
frequency, with some individual mutations being detected in 
97% of the reads, whereas metaplasia samples either retained 
WT p53 or had fewer mutations in lower frequency (Fig.  2 
and Table S2). In the BE clinical setting, p53 status is assessed 
by immunohistochemistry (IHC), a reliable method recom-
mended to aid the dysplasia diagnosis as it detects mutational 
and nonmutational changes leading to p53 inactivation (Bian 
et al., 2001; Kaye et al., 2010; Fitzgerald et al., 2014). Using 
this approach, we confirmed that all dysplasia samples had 
abnormal p53 expression, indicative of p53 mutations or loss, 
whereas most metaplasia samples retained WT p53 expression 
(Fig. S2 and Table S2). Collectively, these results confirm that 
p53 is first altered in dysplasia and suggest that this change 
underlies the increased penetrance of centrosome amplifica-
tion detected at this stage.
Profile of centrosome amplification in cell lines is similar to 
patient samples
To test the consequences of p53 loss in centrosome amplification, 
we took advantage of a well-characterized cell line panel estab-
lished from all stages of BE progression and containing genomic 
alterations found in vivo: metaplasia cells are diploid and have 
WT p53, whereas dysplasia cells are aneuploid and have distinct 
p53 mutations (Fig. S3 A and Table S3; Palanca-Wessels et al., 
2003; Jaiswal et al., 2007). We therefore first asked whether this 
panel showed a similar trend in centriole amplification along 
progression to that observed in patient samples. As compari-
son standards for normal cells, we used native epithelia-derived 
cells (Table S3; Harada et al., 2003). To assess centrioles, we used 
two markers (glutamylated tubulin and centrin) in mitotic cells, 
which normally have four centrioles.
As in tissue samples, centriole amplification was not found 
in normal lining cells, but it was detected in metaplasia cells and 
in all cell lines from the subsequent stages (Fig. 3). Moreover, 
the number of centrioles found per cell increased upon progres-
sion (Fig. S3 B). Importantly, the incidence of centriole amplifi-
cation increased from metaplasia to dysplasia (Fig. 3). This was 
validated with an additional centriolar marker and confirmed 
in interphase cells (Fig. S3, C and D). The higher percentage of 
cells with amplification observed in cell lines compared with 
tissue samples was likely caused by undercounting in tissue 
samples, which resulted from technical limitations (see Materi-
als and methods). Interestingly, we had in our collection both an 
adenocarcinoma cell line (ESO51) and the tumor it was derived 
from (case 8 in cohort 3), and both had a lower degree of ampli-
fication (10% cell line and 2.5% tissue) as compared with the 
other lines and tumors (up to 31.8% cell lines and 6.5% tissues). 
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Collectively, these observations suggest cell lines keep the cen-
trosome characteristics of their tissue of origin and are thus a 
good model to test the molecular changes underlying centro-
some amplification.
WT p53 controls centriole amplification in metaplasia
Previous work showed that p53 loss alone in normal human cells 
does not lead to centrosome number defects. However, loss of p53 
is required for the survival of cells experimentally perturbed to 
gain or lose centrosomes (Cuomo et al., 2008; Holland et al., 2012; 
Lambrus et al., 2015; Wong et al., 2015). Given the small popu-
lation of cells with supernumerary centrioles in metaplasia, we 
hypothesized that there is underlying centrosome amplification 
in metaplasia that is normally suppressed by p53. Cellular stress 
normally induces p53, leading to its nuclear accumulation and 
activation of downstream effectors to prevent the expansion 
of those cells (Rivlin et al., 2011). We found that all interphase 
metaplasia cells with centriole amplification showed p53 nuclear 
accumulation, whereas the majority (70%) of cells with normal 
centriole number had undetectable p53 (Fig. 4 A). To test whether 
p53 was preventing the expansion of cells with amplification, 
we depleted p53 by siRNA (Fig. S3 E). Indeed, p53 depletion in 
metaplasia resulted in an increase in centriole amplification to 
similar levels detected in dysplasia (Fig. 4, B–D). This result was 
Figure 1. Centriole amplification arises early and is associated with tumor initiation in patient samples. (A) BE multistep pathway of progression. Tissue 
samples’ origins are highlighted. Normal lining: native esophageal epithelium. Cohort 1: metaplasia from biopsies of patients that have not progressed. Cohort 
2: dysplasia and adjacent metaplasia as well as foci of adenocarcinoma when present in each patient. Cohort 3: adenocarcinoma and adjacent metaplasia as 
well as lymph node metastasis (met.) when present in each patient. Representative histopathologic features (H&E) of the samples are shown. Bar, 50 mm. 
(B and C) Samples were stained for PCM (pericentrin), centrioles (GT335), and DNA. (B) Representative images with enlargements of cells and centrioles in 
a single cell (arrowheads). Bars: (top) 50 µm; (bottom, main images) 10 µm; (bottom, insets) 1 µm. (C) Quantification of cells with centriole amplification for 
the tissue samples present in each case analyzed. n = 200/tissue/patient. N, number of cases analyzed. Gray lines indicate means of all samples analyzed for 
each tissue of origin.
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confirmed using different p53 siRNAs or shRNA (Fig. S3, F–I). 
Significantly, p53 depletion alone was not sufficient to generate 
centriole amplification in normal lining cells (Fig. S3, J and K). 
It is therefore likely that yet-unidentified molecular changes 
occurring in metaplasia (Weaver et al., 2014) promote centriole 
amplification at this stage.
Importantly, supernumerary centrioles in metaplasia both 
before and after p53 loss were active, as they were able to recruit 
γ-tubulin and nucleate microtubules (Figs. 4 C and S3, L and M), 
thus potentially contributing to genomic instability (Ganem et 
al., 2009; Silkworth et al., 2009). Future studies are needed to 
elucidate the fate of metaplasia cells dividing with supernumer-
ary centrioles. In the absence of p53, an increase in centrosome 
amplification may play a role in tumor initiation by conferring 
the genomic instability required for the acquisition of malignant 
properties. In agreement with this, chromosomal instability was 
detected in metaplasia adjacent to neoplasia and was progres-
sively more frequent in dysplasia and adenocarcinoma (Chaves 
et al., 2007; Paulson et al., 2009).
Centrosome number deregulation can occur by several mech-
anisms including centrosome biogenesis deregulation and cyto-
kinesis failure (Godinho and Pellman, 2014). In the latter, cen-
trosome numbers increase in concert with ploidy (Davoli and de 
Lange, 2011). Ploidy is known to be deregulated in BE tumorigen-
esis: tetraploidy was detected in BE and predicts progression to 
aneuploidy, which is preceded by p53 changes (Reid et al., 2010). 
Moreover, ploidy deregulation is likely also surveyed by p53 
(Thompson and Compton, 2010; Ganem et al., 2014). To test the 
association between deregulation of ploidy and centriole num-
bers, we investigated both features in metaplasia cells with or 
without p53. We detected ploidy deregulation in mitotic metapla-
sia cells (Fig. 4 E) and binucleated cells in metaplasia that elicited 
a p53 response (Fig. S3 N). Ploidy deregulation was aggravated 
upon p53 silencing (Fig. S3, O–Q). Moreover, both centriole num-
ber and ploidy increased upon p53 loss (Fig. 4 E), suggesting a com-
mon origin such as cell division failure. If centriole amplification 
detected upon p53 loss in metaplasia results exclusively from cell 
division failure, then blocking metaplasia cells in S phase and thus 
Figure 2. p53 is deregulated in dysplasia patient samples. The mutational status of p53 in dysplasia and adjacent metaplasia samples (cohort 2) was 
determined by NGS. The positions and frequency of the mutations identified in each patient in metaplasia and dysplasia areas are shown above and below 
the protein schematic, respectively. fs, frameshift mutation; OD, oligomerization domain; RD, regulatory domain; TD, transactivation domain. The asterisk 
indicates a nonsense mutation.
Figure 3. Profile of centriole amplification 
in representative cell lines is similar to that 
in patient samples. (A and B) Cells derived 
from the normal lining and from all stages of 
BE progression were stained for centrioles 
(centrin and GT335) and DNA. (A) Representa-
tive images. Bar, 10 µm. (B) Quantification of 
mitotic cells with centriole amplification in each 
cell line (n ≥ 60/cell line) of the indicated tissue 
of origin. Gray lines indicate means of all cell 
lines for each tissue of origin. Met., metastasis.
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not allowing them to divide should abrogate the increase in ampli-
fication. We found that p53 loss was still able to promote centriole 
amplification in S phase–arrested metaplasia cells (hydroxyurea 
treatment; Fig. 4, F and G; and Fig. S3, R and S), suggesting that 
at least part of the amplification observed does not result from 
failed cell division. Previous work showed that S phase arrest was 
sufficient to generate centrosome amplification in p16-deficient 
human mammary cells (McDermott et al., 2006). However, this 
was not the case in control metaplasia cells (Fig. 4, F and G), which 
also lack the tumor suppressor p16, one of the earliest changes in 
BE (Table S3; Reid et al., 2010). The contribution of this and other 
early events to centrosome amplification deserves further study. 
Collectively, these results suggest centriole amplification can arise 
independently of cell division failure in BE metaplasia and demon-
strate a key role for p53 in preventing the expansion of those cells.
p53 hotspot mutations R175H and R248W deregulate 
centriole number control
As most tumor suppressors, p53 inactivation can be caused 
by nonsense or frameshift mutations that lead to a truncated 
nonfunctional protein. In most cases, however, including BE 
tumorigenesis, p53 contains a missense mutation resulting in 
the expression of a full-length protein that loses the WT func-
tion and may gain oncogenic function (Fig. 2; Rivlin et al., 2011; 
Weaver et al., 2014). Hence, it is relevant to study the effect of 
p53 missense mutations on centrosome number as it could be 
different from loss of WT function. Notably, all three dysplasia 
cell lines, which have either a frameshift mutation or the mis-
sense mutations R175H or R248W, exhibited similar levels of cen-
triole amplification (Fig. 3 B and Table S3). R175H and R248W 
are known hotspot mutations in BE neoplasia and other tumors 
(Fig. 2; Petitjean et al., 2007; Weaver et al., 2014). Expression of 
these mutants in p53−/− MEFs and in a lung metastasis cell line 
led to centrosome amplification (Tarapore et al., 2001; Noll et al., 
2012). In this study, we tested whether expression of R175H or 
R248W mutants prevents the amplification elicited by p53 loss 
in metaplasia (Fig. 5 A). In contrast with expression of WT p53, 
neither mutant prevented the accumulation of cells with ampli-
fication (Fig. 5, B–D). Moreover, amplified centrioles were active 
as they nucleated microtubules (Fig.  5  C). These results show 
both residues are essential for p53 to control centriole number 
in metaplasia and that loss of WT p53 function leads to increase 
in centriole amplification upon progression from metaplasia to 
dysplasia. Moreover, previous findings that R175H and R248W 
Figure 4. p53 represses centriole amplifica-
tion in metaplasia. (A) Metaplasia cells were 
stained for p53, centrioles (centrin and CP110), 
and DNA. Dashed lines denote individual cell 
outlines given by the CP110/centrin back-
ground signal. Insets show centrioles (arrow-
heads) in p53-negative (1) and p53-positive 
(2 and 2’) cells. (B–E) Metaplasia cells trans-
fected with control (GL2) or p53 (TP53) siRNA 
were stained for centrioles (centrin and GT335) 
and DNA (B) or centrioles, microtubules (α-tu-
bulin), and DNA (C). Untreated metaplasia and 
normal lining cells were also analyzed. (B and 
C) Representative images with enlargements of 
centrioles. Bars: (main images) 10 µm; (insets) 
1 µm. (D) Quantification of mitotic cells with 
centriole amplification. n ≥ 100/condition/
experiment. (E) Correlation between centriole 
number and DNA content in each mitotic cell 
(individual circles). Data are from two indepen-
dent experiments. n ≥ 100/condition/experi-
ment; Spearman test. (F and G) Asynchronous 
(−) or S phase–arrested (hydroxyurea [+HU]) 
metaplasia cells transfected with control (GL2) 
or p53 (TP53) siRNA were stained for centri-
oles (centrin) and γ-tubulin. (F) Representative 
images with enlargements of centrioles (arrow-
heads). Bars: (main images) 10 µm; (insets) 1 
µm. (G) Quantification of cells with centriole 
amplification. n ≥ 60/condition/experiment. 
Error bars show means ± SEM of three inde-
pendent experiments. *, P < 0.05; **, P < 0.01; 
***, P < 0.001 (ANO VA). 
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mutations can promote genomic instability and invasion (Rivlin 
et al., 2011; Muller and Vousden, 2014) further support a role for 
centrosome amplification in those processes. Further studies are 
needed to determine how distinct p53 mutations affect tumori-
genesis and whether that is related to centrosome amplification.
In summary, we showed that centrosome amplification (A) is 
never observed in native epithelia, suggesting centriole number 
control is robust in the normal population; (B) it arises as early 
as the premalignant condition and is present in all stages in all 
patients; (C) its incidence is dynamic during progression; (D) it 
significantly increases from metaplasia to dysplasia; and (E) this 
increase correlates with and is dependent on loss of p53 function. 
These findings have important implications in our understand-
ing of centrosome amplification in cancer progression.
An association between p53 loss and centrosome amplifica-
tion is found in several cancers (Chan, 2011). Our findings clar-
ify this relationship in human cancer: centrosome amplification, 
though low in incidence, arises in the context of functional WT 
p53 that plays a crucial role in preventing widespread centro-
some amplification. Our study thus supports the existence of a 
p53-dependent pathway preventing proliferation upon centro-
some number deregulation (Ganem et al., 2014; Lambrus et al., 
2015; Fava et al., 2017). Future work will be important to elucidate 
the mechanisms activating p53 upon centrosome amplification.
Our analysis at the single-cell level also revealed that despite 
the dynamic clonal evolution in BE progression (Reid et al., 2010; 
Weaver et al., 2014), centrosome amplification is never elimi-
nated nor close to 100%. As centrosome amplification leads to 
genomic instability (Ganem et al., 2009; Silkworth et al., 2009), 
ability to invade (Godinho et al., 2014; Kushner et al., 2014), and 
non–cell-autonomous effects (Marusyk et al., 2014; Ganier et al., 
2018), it does not have to be present in a high fraction of cells to 
impact tumor progression. This suggests cells with centrosome 
deregulation may be advantageous at the population level by pro-
moting the fitness of the other cells.
Given widespread occurrence of p53 mutations and centro-
some amplification in human tumors, our findings on the timing 
and ordering of these events and aneuploidy in BE tumorigenesis 
are likely to be extended to other cancers. Moreover, the clarifi-
cation of the relationship between centrosome amplification and 
loss of p53 function suggests that this can be part of a wanting 
gene signature that predicts significant centrosome amplifica-
tion in tumor samples. This could be useful to identify patients 
that will respond to centrosome-related inhibitors currently in 
clinical trials (Godinho and Pellman, 2014; Mason et al., 2014). 
Finally, the cell lines used in this study will be an excellent tool 
to get further insight into how supernumerary centrosomes arise 
and how they contribute to tumor progression, invasiveness, 
and metastasis.
Materials and methods
Patient selection and clinical samples
For the purpose of this study, three cohorts of patients were 
selected from the Pathology Department database of Instituto 
Português de Oncologia de Lisboa Francisco Gentil (IPO LFG). 
Cohort 1: biopsies from six BE patients included in the surveil-
lance program, with metaplasia negative for dysplasia until the 
Figure 5. The p53 hotspot mutations R175H and R248W deregulate centriole numbers in metaplasia. (A–D) Metaplasia cells depleted of endogenous 
p53 (TP53) were transfected with WT p53, p53-R175H, p53-R248W, or the empty plasmid (control). Metaplasia cells transfected with control siRNA (GL2) or 
siRNA against endogenous p53 (TP53) alone were also analyzed. (A) Protein levels were assessed by WB. GAP DH was used as a loading control. (B–D) Cells 
were stained for centrioles (centrin and GT335) and DNA (B) or centrioles, microtubules (α-tubulin), and DNA (C). (B and C) Representative images are shown. 
Bars, 10 µm. (D) Quantification of mitotic cells with centriole amplification. n ≥ 100/condition/experiment. Error bars show means ± SEM of two independent 
experiments. **, P < 0.01; ***, P < 0.001 (ANO VA).
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moment of this study (in a followup from 1998–2012). An addi-
tional set of similar biopsies from another 22 BE patients was 
evaluated separately (Fig. S1 E). Cohort 2: five patients included 
in the surveillance program that were submitted to endoscopic 
resection or esophagectomy upon progression to high-grade 
dysplasia or adenocarcinoma. Cohort 3: 14 patients that when 
first examined already had adenocarcinoma and were submit-
ted to esophagectomy (without neoadjuvant therapy). All forma-
lin-fixed paraffin-embedded (FFPE) samples were selected not 
compromising future diagnostic studies. Areas of metaplasia, 
dysplasia, adenocarcinoma, and/or lymph node metastasis were 
selected. All cases were anonymized after a clinical record review 
for demographic data. Staging and grading were performed 
according to the American Joint Committee on Cancer staging 
system and the World Health Organization criteria, respectively 
(Amin et al., 2010; Bosman et al., 2010). As standards of compar-
ison for normal squamous- and columnar-lined mucosa, respec-
tively, the squamous-lined mucosa from the proximal margin 
of 14 total gastrectomies for gastric adenocarcinoma and the 
ileal mucosa from the proximal margin of 14 right-hemicolec-
tomies for intestinal adenocarcinoma were used. Material from 
BE patients was obtained in the context of IPO LFG surveillance 
program and was used without compromising future patient 
management. All samples were routinely anonymized upon col-
lection for the archival file, thus guaranteeing the privacy, con-
fidentiality, and protection of patients and their personal data. 
This study was approved by the IPO LFG Research Council and 
Ethics committee.
Cell culture
Human telomerase-immortalized (hTERT) BAR-T and BAR-T10 
cell lines derived from biopsies of patients with nondysplastic BE 
as well as BAR-T cell lines expressing the pSUP ER-p53RNAi or the 
control empty vector pSUP ER-retro.neo (all from R. Souza, Baylor 
University Medical Center, Dallas, TX; Jaiswal et al., 2007; Zhang 
et al., 2010) were cocultured with a fibroblast feeder layer (Swiss 
3T3 cells [85022108; European Collection of Authenticated Cell 
Cultures] treated with 10 µg/ml mitomycin C [Sigma-Aldrich] 
for 2 h) and maintained in KBM2 medium (Lonza) supplemented 
with 5% FBS, 0.1 nM cholera toxin (Sigma-Aldrich), 70 µg/ml 
bovine pituitary extract (BPE; Sigma-Aldrich), 400 ng/ml hydro-
cortisone (Sigma-Aldrich), 20 ng/ml EGF, 20 µg/ml adenine 
(Sigma-Aldrich), 5 µg/ml insulin (Sigma-Aldrich), 5 µg/ml trans-
ferrin (Gibco), and 100 U/ml penicillin-streptomycin (Gibco). 
Cells were seeded in wells precoated with collagen IV (1 µg/cm2; 
Sigma-Aldrich) for individual experiments. hTERT CP-B, CP-C, 
and CP-D cell lines derived from biopsies of patients with high-
grade dysplasia (from P. Rabinovitch, University of Washington, 
Seattle, WA; Palanca-Wessels et al., 2003) were maintained in 
MCDB 153 medium (Sigma-Aldrich) supplemented with 5% FBS, 
0.4 µg/ml hydrocortisone, 20 ng/ml EGF, 1 nM cholera toxin, 140 
µg/ml BPE, 20 µg/ml adenine, 4  mM glutamine (Gibco), 0.1% 
insulin-transferrin-sodium selenite (Sigma-Aldrich), and 100 U/
ml penicillin-streptomycin. Adenocarcinoma-derived cell lines 
ESO26, ESO51 (both established previously; Boonstra et al., 2010), 
OE19, OE33, FLO-1, SK-GT-4, OACP4, KYAE-1, and lymph node 
metastasis-derived cell line OACM5.1 (from W. Dinjens, Erasmus 
Medical Center Cancer Institute, Rotterdam, Netherlands) were 
grown in RPMI 1640 or in RPMI 1640–Ham’s F12 (Kyae-1 cell line) 
supplemented with 10% FBS and 100 U/ml penicillin-streptomy-
cin. The ESO51 cell line was derived from the tumor in case 8 
from cohort 3 (Table S1). All cell lines have been recently vali-
dated (Boonstra et al., 2010). As standards of comparison for 
normal cells, we used hTERT normal esophageal epithelial cells 
(EPC2; from S. Godinho, Barts Cancer Institute, London, England, 
UK) as well as a common experimentally used nontransformed 
hTERT cell line derived from normal human RPE1. hTERT-ECP2 
was grown in keratinocyte-serum-free medium with glutamine 
supplemented with EGF, BPE (Gibco), and 100 U/ml penicil-
lin-streptomycin (Harada et al., 2003), and hTERT-RPE1 cells 
were grown in DMEM-F12 (Gibco) supplemented with sodium 
bicarbonate, 10% FBS, and 100 U/ml penicillin-streptomycin. All 
cells were grown at 37°C in a 5% CO2 atmosphere and tested for 
the presence of mycoplasma.
IF microscopy
Tissue samples
From each FFPE block, 3-µm-thick tissue sections were trans-
ferred to positively charged glass slides and oven dried (70°C) for 
at least 1 h. Sections were then deparaffinized in xylene, placed 
in 100% ethanol, treated with 2% hydrogen peroxide in methanol 
solution for 10 min to block the endogenous peroxidase, and then 
washed in distilled water. Antigen retrieval was done in a pres-
sure cooker in a 0.01-M sodium citrate–buffered solution, pH 
6, for 6 min followed by incubation with a blocking buffer (TBS 
with 5% BSA) for 10 min at RT. Slides were then incubated with 
primary antibodies diluted in Bond primary antibody diluent 
(Leica Microsystems) with background-reducing components 
for 1 h at RT followed by washes in TBS before incubation with 
secondary antibodies for 30 min at 37°C. Slides were then washed 
extensively with TBS, dehydrated through gradient alcohols, 
and mounted in Vectashield with DAPI for DNA staining (Vector 
Laboratories). 
Cell lines
Cells were grown on coverslips and were fixed with ice-cold 
methanol at −20°C for 10 min. Standard IF procedures involved 
blocking (30 min) and antibody incubations (overnight at 4°C 
for 1 h at RT) in PBS with 10% FBS, and washes were performed 
in PBS. Coverslips were mounted on glass slides in Vectashield 
with DAPI (Vector Laboratories). For DNA content analysis by IF, 
coverslips were incubated for 10 min in PBS with 1 µg/ml Hoechst 
33342 (Invitrogen) before being mounted in Vectashield (Vector 
Laboratories). 
Image acquisition
Images were obtained at RT using a Ti-E inverted microscope 
(Nikon) with a Plan Apochromat VC 100× 1.40 NA oil objec-
tive, an ORCA ER2 charge-coupled device camera (Hamamatsu 
Photonics), and Nikon software or with an Eclipse Ti-E (Nikon) 
microscope with a Plan Apochromat 100× 1.49 NA oil objective, 
an Evolve electron-multiplying charge-coupled device camera 
(Photometrics), and MetaMorph software (Molecular Devices). 
Images were acquired as a z series (0.2-µm z interval) and are 
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presented as maximum-intensity projections. Images were 
prepared using Photoshop (Adobe) and ImageJ (National Insti-
tutes of Health). 
Antibodies
Primary antibodies used were against glutamylated tubulin 
(1:800 [tissue sections] and 1:500 [cell lines]; mouse; GT335; 
AdipoGen), pericentrin (1:250; rabbit; ab4448; Abcam), centrin 
(1:500; rabbit; N-17; Santa Cruz Biotechnology, Inc.), centrin 
(1:500; mouse; 20H5; EMD Millipore), A647-conjugated centrin 
(1:500; mouse; 20H5; EMD Millipore), γ-tubulin (1:500; mouse; 
GTU88; Sigma-Aldrich), α-tubulin (1:50; rat; YL1/2; AbD Sero-
tec), p53 (1:100; mouse; DO-1; EMD Millipore), E-cadherin (1:30; 
rabbit; Cell Signaling Technology), and CP110 (1:250; rabbit; Jiang 
et al., 2012). The secondary antibodies FITC, Cy5, and rhodamine 
red (1:50 [tissue sections] and 1:200 [cell lines]; Jackson Immu-
noResearch Laboratories, Inc.) as well as Alexa Fluor 488 and 647 
(1:500 [cell lines]; Thermo Fisher Scientific) were also used.
Centrosome/centriole number and DNA content analysis by IF
Tissue samples
We used two markers that have robust staining in paraffin-em-
bedded samples and that label the two structural components of 
the centrosome: the centrioles (marked by glutamylated tubu-
lin [GT335]) and the PCM (marked by pericentrin). Centriole 
number was assessed by GT335 when it colocalized with peri-
centrin, thus identifying centrosomes. To achieve good staining 
and resolution at the cellular level, we used thin tissue samples 
(3 µm thick, as normally used in the clinic). Immunostaining of 
centrosomes was judged satisfactory when it was detected in the 
adjacent epithelium. The analysis was done taking into consider-
ation the limitations derived from the specificities of working in 
FFPE samples: cellular truncation and cell overlapping. We first 
tested our accuracy of counting centrioles using GT335 marker 
with or without a costaining with a membrane marker (E-cad-
herin) and found that the background of GT335 staining was 
sufficient to distinguish cell limits and that the results obtained 
were similar. The counts were performed by going through all the 
z series acquired (see IF microscopy section) covering the whole 
depth of the section to assess the transversal and sagittal plans 
of each cell, thus identifying the transition to adjacent cells. Cells 
whose limits could not be clearly distinguished as well as cells 
overlapping with neighboring cells were not considered. To test 
for the occurrence of undercounting and overcounting related 
to the usage of histological sections, we did an extensive analysis 
in our standards of comparison for normal cells (14 ileum and 14 
squamous) that were cut at the same thickness as all the other 
samples. Given that this analysis was performed in typically 
well-differentiated areas (i.e., not proliferative), the number of 
centrosomes expected per cell was one (with two centrioles). 
Whereas we detected an expected undercounting (cells with 0 
centrioles), we never detected an overcounting (cells with more 
than two centrioles), suggesting that the method used to distin-
guish cell limits was robust. In each case, at least 200 countable 
cells with centrosomes were examined. Depending on the cell 
cycle stage, a cell either has one centrosome with two centrioles 
(G1) or two centrosomes with two centrioles each (S, G2, and M; 
Bettencourt-Dias et al., 2011). Because we did not use a cell cycle 
stage marker, only cells with more than four centrioles were con-
sidered to contain an abnormal centriole number content (cen-
triole amplification).
Cell lines
Centrioles were considered when paired signals of two centriole 
markers (GT335, centrin, or CP110) were observed or when a cen-
triole marker (centrin) colocalized with a PCM marker (γ-tubu-
lin). For cell-by-cell centriole number and DNA content analysis 
in mitotic cells, sum projections of DNA staining (Hoechst) were 
used to determine total intensity of signal as measured by ImageJ 
software (National Institutes of Health). Total intensity was cor-
rected according to the background intensity signal: corrected 
total cell fluorescence = integrated density – (area of selected cell 
× mean fluorescence of background readings). The number of 
cells and samples analyzed, number of experiments performed, 
and statistical analyses are detailed in the figure legends.
DNA extraction and p53 next-generation sequencing (NGS)
FFPE tissue sections (5 µm) were deparaffinized and counter-
stained with H&E. Metaplasia- and dysplasia-enriched areas 
were microdissected with a needle under pathologist’s guidance. 
Total DNA was extracted with GeneRead DNA FFPE kit (QIA GEN) 
according to the manufacturer’s instructions with a slight modi-
fication: proteinase K cell lysis at 56°C was performed overnight. 
DNA was eluted in 20 µl of elution buffer. To evaluate DNA con-
centration and integrity, DNA isolated from each sample was 
quantified in TapeStation 2200 using the Genomic DNA Scre-
enTape (Agilent Technologies). Because of the small amounts 
of extracted DNA from each sample area, DNA was precipitated 
according to the sodium acetate precipitation of small nuclei 
acids protocol (Thermo Fisher Scientific). Genomic DNA libraries 
were prepared using the Ion Ampliseq Library kit (2.0) as well as 
the community panel Ion Ampliseq TP53 and quantified by quan-
titative PCR with the Ion Library Quantification kit (Thermo 
Fisher Scientific). The emulsion PCR of amplified libraries was 
performed using Ion Chef (Thermo Fisher Scientific). Sequenc-
ing runs were performed with Ion personal machine using 316 
Chips (Thermo Fisher Scientific) aiming for a mean sequencing 
depth coverage of 500×. With the exception of one sample where 
the amount of DNA was too low for robust analysis, we were able 
to sequence all coding exons of p53 by NGS in all paired samples.
Analysis of p53 by IHC
Analysis was performed as currently used to assess p53 in mor-
phological lesions using tissue samples. Staining of p53 (1:150; 
mouse; DO-7; Cell Marque) was performed on either a fully auto-
mated IHC BOND III system (Leica Biosystems) using ER1 solu-
tion (15 min) for antigen retrieval and Novocastra bond polymer 
refine detection or on a Ventana Benchmark Ultra (Roche) using 
the CC1 solution (24 min) for antigen retrieval and an OptiView 
DAB IHC detection kit (Ventana). An expert pathologist qualita-
tively evaluated p53 immunostaining as WT, positive, or nega-
tive. WT expression: weak positivity similar to the observed in 
the normal native epithelium (internal control). Positive expres-
sion: the intensity of staining was graded as weak, moderate, or 
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intense compared with the native epithelium and as focal or dif-
fuse according to the amount of positive cells (<10% vs. >10%). 
Negative expression: complete absence or only occasional scat-
tered positive cells within a context of WT staining (metaplasia 
or native epithelium).
RNAi, transfection, and drug treatment
Endogenous TP53 was depleted using siRNA oligonucleotides 
(5′-GGG AGT TGT CAA GTC TCTG-3′; Sigma-Aldrich) targeting the 
3′ UTR region. The TP53 gene was alternatively depleted using 
other siRNA oligonucleotides: TP531 (sc-29435; Santa Cruz Bio-
technology, Inc.) or TP532 (5′-GAC TCC AGT GGT AAT CTAC-3′; 
Sigma-Aldrich; same sequence as in BAR-T–pSUP ER-p53RNAi 
cell line [Brummelkamp et al., 2002]). Luciferase (GL2) siRNA 
(5′-CGT ACG CGG AAT ACT TCGA-3′; Takara Bio Inc.) was used as a 
control. Cells were transfected with 50 nM siRNA for 72 h using 
Lipofectamine RNAiMAX (Thermo Fisher Scientific). For S phase 
arrest, 16 h after siRNA treatment, cells were treated with 4 mM 
hydroxyurea (Sigma-Aldrich) for 48 h. Transient plasmid trans-
fections were performed with Lipofectamine LTX (Invitrogen) 
according to the manufacturer’s instructions 16 h after siRNA 
transfection and were analyzed after 48 h. p53 constructs were 
obtained from Addgene (Baker et al., 1990).
Cell lysis, SDS-PAGE, and Western blotting (WB)
Cells were harvested and pelleted before snap freezing in liquid 
nitrogen. Cell lysates were prepared by resuspending pellets in 
lysis buffer (50 mM Hepes, pH 7.4, 100 mM KCl, 1 mM EGTA, 
1 mM MgCl2, 10% glycerol, 0.05% NP-40, 1× protease inhibitor 
cocktail, and 1× phosphatase inhibitor cocktail) for 10 min on 
ice. Lysates were then centrifuged for 10 min at 14,000 rpm at 
4°C, and protein concentration of the cleared supernatant was 
determined by Bradford assay. Laemmli buffer was added to 
the samples to 1× and then boiled at 99°C for 5 min before anal-
ysis on polyacrylamide gels. Standard WB procedures involved 
blocking in TBS supplemented with 5% milk powder and 1% milk 
powder in TBS-T (0.1% Tween-20 in TBS) for antibody incuba-
tions, and washes were performed in TBS-T. Primary antibodies 
were against p53 (1:1,000; mouse) and GAP DH (1:1,000; rabbit; 
14C10; Cell Signaling Technology). IRDye secondary antibodies 
were used at 1:10,000 and were purchased from Odyssey and 
LI-COR Biosciences.
Cell cycle phase distribution and DNA content analysis 
by flow cytometry
Cells were harvested, pelleted, and washed in 1× PBS before 
being fixed in 70% ice-cold ethanol and kept on ice for 30 min. 
After washes with 1× PBS, cells were resuspended in 1× PBS with 
100 µg/ml RNase A (QIA GEN) and 100 µg/ml propidium iodide 
(Sigma-Aldrich) and incubated at 37°C for 30 min in the dark. 
Cells were then analyzed with FACScan (BD).
Online supplemental material
Fig. S1 shows analysis of centriole numbers in patient samples. 
Fig. S2 shows analysis of p53 status in patient samples by IHC. 
Fig. S3 shows centriole number and ploidy in cell lines. Table S1 
shows centriole number analysis in paraffin-embedded tissue. 
Table S2 shows analysis of p53 status. Table S3 shows cell line 
information and centriole analysis.
Acknowledgments
We thank S. Esteves (IPO LFG) for statistical analysis and the 
M. Bettencourt-Dias laboratory members A. Fry, S. Godinho, R. 
Souza, S. Spechler, F. Janody, L. David, A. Holland, and C. Martins 
for useful discussion. We are grateful to W. Dinjens, R. Souza, S. 
Godinho, and P. Rabinovitch for cell lines. 
This work was funded by Fundação para a Ciência e a Tec-
nologia–Harvard Medical School Program Portugal (HMSP-CT/
SAU-ICT/0075/2009), Liga Portuguesa Contra o Cancro, Euro-
pean Molecular Biology Organization Installation, and Sociedade 
Portuguesa de Gastroenterologia. 
The authors declare no competing financial interests.
Authors contributions: C.A.M. Lopes and M. Mesquita 
designed and performed experiments, analyzed and interpreted 
data, and wrote the manuscript. A.I. Cunha, S. Carapeta, C. Laran-
jeira, and A.E. Pinto performed experiments. J. Cardoso designed 
and performed experiments and analyzed and interpreted data. 
J.B. Pereira-Leal discussed experimental design. A. Dias-Pereira 
discussed experimental design and edited the manuscript. M. 
Bettencourt-Dias and P. Chaves discussed experimental design, 
interpreted and discussed the data, and edited the manuscript.
Submitted: 1 December 2017
Revised: 7 April 2018
Accepted: 17 April 2018
References
Amin, M.B., S. Edge, F. Greene, D.R. Byrd, R.K. Brookland, M.K. Washington, 
J.E. Gershenwald, C.C. Compton, K.R. Hess, D.C. Sullivan, et al. 2010. AJCC 
Cancer Staging Manual. Sixth edition. Springer, New York. 1032 pp.
Baker, S.J., S. Markowitz, E.R. Fearon, J.K.V. Willson, and B. Vogelstein. 1990. 
Suppression of human colorectal carcinoma cell growth by wild-type 
p53. Science. 249:912–915. https:// doi .org/ 10 .1126/ science .2144057
Bettencourt-Dias, M., F. Hildebrandt, D. Pellman, G. Woods, and S.A. Godinho. 
2011. Centrosomes and cilia in human disease. Trends Genet. 27:307–315. 
https:// doi .org/ 10 .1016/ j .tig .2011 .05 .004
Bian, Y.S., M.C. Osterheld, F.T. Bosman, J. Benhattar, and C. Fontolliet. 2001. 
p53 gene mutation and protein accumulation during neoplastic progres-
sion in Barrett’s esophagus. Mod. Pathol. 14:397–403. https:// doi .org/ 10 
.1038/ modpathol .3880324
Boonstra, J.J., R. van Marion, D.G. Beer, L. Lin, P. Chaves, C. Ribeiro, A.D. Pereira, 
L. Roque, S.J. Darnton, N.K. Altorki, et al. 2010. Verification and unmask-
ing of widely used human esophageal adenocarcinoma cell lines. J. Natl. 
Cancer Inst. 102:271–274. https:// doi .org/ 10 .1093/ jnci/ djp499
Bornens, M. 2012. The centrosome in cells and organisms. Science. 335:422–
426. https:// doi .org/ 10 .1126/ science .1209037
Bosman, F.T., F. Carneiro, R.H. Hruban, and N.D. Theise. 2010. WHO Classifi-
cation of Tumours of the Digestive System. Fourth edition. WHO press, 
Geneva, Switzerland. 417 pp.
Brummelkamp, T.R., R. Bernards, and R. Agami. 2002. A system for stable 
expression of short interfering RNAs in mammalian cells. Science. 
296:550–553. https:// doi .org/ 10 .1126/ science .1068999
Chan, J.Y. 2011. A clinical overview of centrosome amplification in human 
cancers. Int. J. Biol. Sci. 7:1122–1144. https:// doi .org/ 10 .7150/ ijbs .7 .1122
Chaves, P., M. Crespo, C. Ribeiro, C. Laranjeira, A.D. Pereira, A. Suspiro, P. 
Cardoso, C.N. Leitão, and J. Soares. 2007. Chromosomal analysis of Bar-
rett’s cells: demonstration of instability and detection of the metaplas-
tic lineage involved. Mod. Pathol. 20:788–796. https:// doi .org/ 10 .1038/ 
modpathol .3800787
Lopes et al. 
Centrosome amplification arises before neoplasia
Journal of Cell Biology
https://doi.org/10.1083/jcb.201711191
10
Coelho, P.A., L. Bury, M.N. Shahbazi, K. Liakath-Ali, P.H. Tate, S. Wormald, 
C.J. Hindley, M. Huch, J. Archer, W.C. Skarnes, et al. 2015. Over-expres-
sion of Plk4 induces centrosome amplification, loss of primary cilia and 
associated tissue hyperplasia in the mouse. Open Biol. 5:150209. https:// 
doi .org/ 10 .1098/ rsob .150209
Cuomo, M.E., A. Knebel, N. Morrice, H. Paterson, P. Cohen, and S. Mittnacht. 
2008. p53-Driven apoptosis limits centrosome amplification and 
genomic instability downstream of NPM1 phosphorylation. Nat. Cell 
Biol. 10:723–730. https:// doi .org/ 10 .1038/ ncb1735
Davoli, T., and T. de Lange. 2011. The causes and consequences of polyploidy 
in normal development and cancer. Annu. Rev. Cell Dev. Biol. 27:585–610. 
https:// doi .org/ 10 .1146/ annurev -cellbio -092910 -154234
Del Portillo, A., S.M. Lagana, Y. Yao, T. Uehara, N. Jhala, T. Ganguly, P. Nagy, J. 
Gutierrez, A. Luna, J. Abrams, et al. 2015. Evaluation of mutational test-
ing of preneoplastic Barrett’s mucosa by next-generation sequencing of 
formalin-fixed, paraffin-embedded endoscopic samples for detection of 
concurrent dysplasia and adenocarcinoma in Barrett’s esophagus. J. Mol. 
Diagn. 17:412–419. https:// doi .org/ 10 .1016/ j .jmoldx .2015 .02 .006
Fava, L.L., F. Schuler, V. Sladky, M.D. Haschka, C. Soratroi, L. Eiterer, E. 
Demetz, G. Weiss, S. Geley, E.A. Nigg, and A. Villunger. 2017. The PID-
Dosome activates p53 in response to supernumerary centrosomes. Genes 
Dev. 31:34–45. https:// doi .org/ 10 .1101/ gad .289728 .116
Fitzgerald, R.C., M. di Pietro, K. Ragunath, Y. Ang, J.-Y. Kang, P. Watson, N. 
Trudgill, P. Patel, P.V. Kaye, S. Sanders, et al. British Society of Gastro-
enterology. 2014. British Society of Gastroenterology guidelines on 
the diagnosis and management of Barrett’s oesophagus. Gut. 63:7–42. 
https:// doi .org/ 10 .1136/ gutjnl -2013 -305372
Ganem, N.J., S.A. Godinho, and D. Pellman. 2009. A mechanism linking extra 
centrosomes to chromosomal instability. Nature. 460:278–282. https:// 
doi .org/ 10 .1038/ nature08136
Ganem, N.J., H. Cornils, S.Y. Chiu, K.P. O’Rourke, J. Arnaud, D. Yimlamai, M. 
Théry, F.D. Camargo, and D. Pellman. 2014. Cytokinesis failure triggers 
hippo tumor suppressor pathway activation. Cell. 158:833–848. https:// 
doi .org/ 10 .1016/ j .cell .2014 .06 .029
Ganier, O., D. Schnerch, P. Oertle, R.Y.H. Lim, M. Plodinec, and E.A. Nigg. 2018. 
Structural centrosome aberrations promote non-cell-autonomous inva-
siveness. EMBO J. 37:e98576. https:// doi .org/ 10 .15252/ embj .201798576
Gleeson, C.M., J.M. Sloan, J.A. McGuigan, A.J. Ritchie, and S.E.H. Russell. 1995. 
Base transitions at CpG dinucleotides in the p53 gene are common in 
esophageal adenocarcinoma. Cancer Res. 55:3406–3411.
Gleeson, C.M., J.M. Sloan, D.T. McManus, P. Maxwell, K. Arthur, J.A. McGuigan, 
A.J. Ritchie, and S.E.H. Russell. 1998. Comparison of p53 and DNA con-
tent abnormalities in adenocarcinoma of the oesophagus and gastric 
cardia. Br. J. Cancer. 77:277–286. https:// doi .org/ 10 .1038/ bjc .1998 .44
Godinho, S.A., and D. Pellman. 2014. Causes and consequences of centro-
some abnormalities in cancer. Philos. Trans. R. Soc. Lond. B Biol. Sci. 
369:20130467. https:// doi .org/ 10 .1098/ rstb .2013 .0467
Godinho, S.A., R. Picone, M. Burute, R. Dagher, Y. Su, C.T. Leung, K. Polyak, 
J.S. Brugge, M. Théry, and D. Pellman. 2014. Oncogene-like induction 
of cellular invasion from centrosome amplification. Nature. 510:167–171. 
https:// doi .org/ 10 .1038/ nature13277
Haggitt, R.C. 1994. Barrett’s esophagus, dysplasia, and adenocarcinoma. Hum. 
Pathol. 25:982–993. https:// doi .org/ 10 .1016/ 0046 -8177(94)90057 -4
Hamelin, R., J.-F. Fléjou, F. Muzeau, F. Potet, P. Laurent-Puig, F. Fékété, and G. 
Thomas. 1994. TP53 gene mutations and p53 protein immunoreactivity 
in malignant and premalignant Barrett’s esophagus. Gastroenterology. 
107:1012–1018. https:// doi .org/ 10 .1016/ 0016 -5085(94)90225 -9
Harada, H., H. Nakagawa, K. Oyama, M. Takaoka, C.D. Andl, B. Jacobmeier, A. 
von Werder, G.H. Enders, O.G. Opitz, and A.K. Rustgi. 2003. Telomerase 
induces immortalization of human esophageal keratinocytes without 
p16INK4a inactivation. Mol. Cancer Res. 1:729–738.
Holland, A.J., D. Fachinetti, Q. Zhu, M. Bauer, I.M. Verma, E.A. Nigg, and D.W. 
Cleveland. 2012. The autoregulated instability of Polo-like kinase 4 lim-
its centrosome duplication to once per cell cycle. Genes Dev. 26:2684–
2689. https:// doi .org/ 10 .1101/ gad .207027 .112
Hvid-Jensen, F., L. Pedersen, A.M. Drewes, H.T. Sørensen, and P. Funch-Jen-
sen. 2011. Incidence of adenocarcinoma among patients with Barrett’s 
esophagus. N. Engl. J. Med. 365:1375–1383. https:// doi .org/ 10 .1056/ 
NEJMoa1103042
Jaiswal, K.R., C.P. Morales, L.A. Feagins, K.G. Gandia, X. Zhang, H.Y. Zhang, K. 
Hormi-Carver, Y. Shen, F. Elder, R.D. Ramirez, et al. 2007. Characteriza-
tion of telomerase-immortalized, non-neoplastic, human Barrett’s cell 
line (BAR-T). Dis. Esophagus. 20:256–264. https:// doi .org/ 10 .1111/ j .1442 
-2050 .2007 .00683 .x
Jiang, K., G. Toedt, S. Montenegro Gouveia, N.E. Davey, S. Hua, B. van der 
Vaart, I. Grigoriev, J. Larsen, L.B. Pedersen, K. Bezstarosti, et al. 2012. 
A Proteome-wide screen for mammalian SxIP motif-containing micro-
tubule plus-end tracking proteins. Curr. Biol. 22:1800–1807. https:// doi 
.org/ 10 .1016/ j .cub .2012 .07 .047
Kaye, P.V., S.A. Haider, P.D. James, I. Soomro, J. Catton, S.L. Parsons, K. Ragu-
nath, and M. Ilyas. 2010. Novel staining pattern of p53 in Barrett’s dys-
plasia--the absent pattern. Histopathology. 57:933–935. https:// doi .org/ 
10 .1111/ j .1365 -2559 .2010 .03715 .x
Kushner, E.J., L.S. Ferro, J.Y. Liu, J.R. Durrant, S.L. Rogers, A.C. Dudley, and V.L. 
Bautch. 2014. Excess centrosomes disrupt endothelial cell migration via 
centrosome scattering. J. Cell Biol. 206:257–272. https:// doi .org/ 10 .1083/ 
jcb .201311013
Lambrus, B.G., Y. Uetake, K.M. Clutario, V. Daggubati, M. Snyder, G. Sluder, 
and A.J. Holland. 2015. p53 protects against genome instability follow-
ing centriole duplication failure. J. Cell Biol. 210:63–77. https:// doi .org/ 
10 .1083/ jcb .201502089
Levine, M.S., B. Bakker, B. Boeckx, J. Moyett, J. Lu, B. Vitre, D.C. Spierings, 
P.M. Lansdorp, D.W. Cleveland, D. Lambrechts, et al. 2017. Centrosome 
Amplification Is Sufficient to Promote Spontaneous Tumorigenesis in 
Mammals. Dev. Cell. 40:313–322.e5. https:// doi .org/ 10 .1016/ j .devcel .2016 
.12 .022
Marthiens, V., M.A. Rujano, C. Pennetier, S. Tessier, P. Paul-Gilloteaux, and 
R. Basto. 2013. Centrosome amplification causes microcephaly. Nat. Cell 
Biol. 15:731–740. https:// doi .org/ 10 .1038/ ncb2746
Marusyk, A., D.P. Tabassum, P.M. Altrock, V. Almendro, F. Michor, and K. 
Polyak. 2014. Non-cell-autonomous driving of tumour growth supports 
sub-clonal heterogeneity. Nature. 514:54–58. https:// doi .org/ 10 .1038/ 
nature13556
Mason, J.M., D.C. Lin, X. Wei, Y. Che, Y. Yao, R. Kiarash, D.W. Cescon, G.C. 
Fletcher, D.E. Awrey, M.R. Bray, et al. 2014. Functional characterization 
of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer 
agent. Cancer Cell. 26:163–176. https:// doi .org/ 10 .1016/ j .ccr .2014 .05 .006
McDermott, K.M., J. Zhang, C.R. Holst, B.K. Kozakiewicz, V. Singla, and T.D. 
Tlsty. 2006. p16INK4a prevents centrosome dysfunction and genomic 
instability in primary cells. PLoS Biol. 4:350–365. https:// doi .org/ 10 
.1371/ journal .pbio .0040051
Muller, P.A.J., and K.H. Vousden. 2014. Mutant p53 in cancer: new functions 
and therapeutic opportunities. Cancer Cell. 25:304–317. https:// doi .org/ 
10 .1016/ j .ccr .2014 .01 .021
Noll, J.E., J. Jeffery, F. Al-Ejeh, R. Kumar, K.K. Khanna, D.F. Callen, and P.M. 
Neilsen. 2012. Mutant p53 drives multinucleation and invasion through 
a process that is suppressed by ANK RD11. Oncogene. 31:2836–2848. 
https:// doi .org/ 10 .1038/ onc .2011 .456
Palanca-Wessels, M.C.A., A. Klingelhutz, B.J. Reid, T.H. Norwood, K.E. Opheim, 
T.G. Paulson, Z. Feng, and P.S. Rabinovitch. 2003. Extended lifespan of 
Barrett’s esophagus epithelium transduced with the human telomerase 
catalytic subunit: a useful in vitro model. Carcinogenesis. 24:1183–1190. 
https:// doi .org/ 10 .1093/ carcin/ bgg076
Paulson, T.G., C.C. Maley, X. Li, H. Li, C.A. Sanchez, D.L. Chao, R.D. Odze, T.L. 
Vaughan, P.L. Blount, and B.J. Reid. 2009. Chromosomal instability and 
copy number alterations in Barrett’s esophagus and esophageal adeno-
carcinoma. Clin. Cancer Res. 15:3305–3314. https:// doi .org/ 10 .1158/ 1078 
-0432 .CCR -08 -2494
Petitjean, A., E. Mathe, S. Kato, C. Ishioka, S.V. Tavtigian, P. Hainaut, and 
M. Olivier. 2007. Impact of mutant p53 functional properties on TP53 
mutation patterns and tumor phenotype: lessons from recent develop-
ments in the IARC TP53 database. Hum. Mutat. 28:622–629. https:// doi 
.org/ 10 .1002/ humu .20495
Reid, B.J., X. Li, P.C. Galipeau, and T.L. Vaughan. 2010. Barrett’s oesophagus 
and oesophageal adenocarcinoma: time for a new synthesis. Nat. Rev. 
Cancer. 10:87–101. https:// doi .org/ 10 .1038/ nrc2773
Rivlin, N., R. Brosh, M. Oren, and V. Rotter. 2011. Mutations in the p53 
Tumor Suppressor Gene: Important Milestones at the Various Steps 
of Tumorigenesis. Genes Cancer. 2:466–474. https:// doi .org/ 10 .1177/ 
1947601911408889
Ross-Innes, C.S., J. Becq, A. Warren, R.K. Cheetham, H. Northen, M. O’Dono-
van, S. Malhotra, M. di Pietro, S. Ivakhno, M. He, et al. 2015. Whole-ge-
nome sequencing provides new insights into the clonal architecture 
of Barrett’s esophagus and esophageal adenocarcinoma. Nat. Genet. 
47:1038–1046. https:// doi .org/ 10 .1038/ ng .3357
Schouten, L.J., J. Steevens, C.J.R. Huysentruyt, C.E. Coffeng, Y.C.A. Keulemans, 
F.E. van Leeuwen, A.L.C. Driessen, and P.A. van den Brandt. 2011. 
Total cancer incidence and overall mortality are not increased among 
Lopes et al. 
Centrosome amplification arises before neoplasia
Journal of Cell Biology
https://doi.org/10.1083/jcb.201711191
11
patients with Barrett’s esophagus. Clin. Gastroenterol. Hepatol. 9:754–761. 
https:// doi .org/ 10 .1016/ j .cgh .2011 .04 .008
Serçin, Ö., J.-C. Larsimont, A.E. Karambelas, V. Marthiens, V. Moers, B. Boeckx, 
M. Le Mercier, D. Lambrechts, R. Basto, and C. Blanpain. 2016. Transient 
PLK4 overexpression accelerates tumorigenesis in p53-deficient epider-
mis. Nat. Cell Biol. 18:100–110. https:// doi .org/ 10 .1038/ ncb3270
Silkworth, W.T., I.K. Nardi, L.M. Scholl, and D. Cimini. 2009. Multipolar spin-
dle pole coalescence is a major source of kinetochore mis-attachment 
and chromosome mis-segregation in cancer cells. PLoS One. 4:e6564. 
https:// doi .org/ 10 .1371/ journal .pone .0006564
Spechler, S.J., P. Sharma, R.F. Souza, J.M. Inadomi, and N.J. Shaheen. American 
Gastroenterological Association. 2011. American Gastroenterological Asso-
ciation Technical Review on the Management of Barrett’s Esophagus. Gas-
troenterology. 140:1084–1091. https:// doi .org/ 10 .1053/ j .gastro .2011 .01 .031
Stachler, M.D., A. Taylor-Weiner, S. Peng, A. McKenna, A.T. Agoston, R.D. 
Odze, J.M. Davison, K.S. Nason, M. Loda, I. Leshchiner, et al. 2015. Paired 
exome analysis of Barrett’s esophagus and adenocarcinoma. Nat. Genet. 
47:1047–1055. https:// doi .org/ 10 .1038/ ng .3343
Tarapore, P., Y. Tokuyama, H.F. Horn, and K. Fukasawa. 2001. Difference in 
the centrosome duplication regulatory activity among p53 ‘hot spot’ 
mutants: potential role of Ser 315 phosphorylation-dependent centro-
some binding of p53. Oncogene. 20:6851–6863. https:// doi .org/ 10 .1038/ 
sj .onc .1204848
Thompson, S.L., and D.A. Compton. 2010. Proliferation of aneuploid human 
cells is limited by a p53-dependent mechanism. J. Cell Biol. 188:369–381. 
https:// doi .org/ 10 .1083/ jcb .200905057
Weaver, J.M.J., C.S. Ross-Innes, N. Shannon, A.G. Lynch, T. Forshew, M. Bar-
bera, M. Murtaza, C.-A.J. Ong, P. Lao-Sirieix, M.J. Dunning, et al. OCC 
AMS consortium. 2014. Ordering of mutations in preinvasive disease 
stages of esophageal carcinogenesis. Nat. Genet. 46:837–843. https:// doi 
.org/ 10 .1038/ ng .3013
Wong, Y.L., J.V. Anzola, R.L. Davis, M. Yoon, A. Motamedi, A. Kroll, C.P. Seo, J.E. 
Hsia, S.K. Kim, J.W. Mitchell, et al. 2015. Reversible centriole depletion 
with an inhibitor of Polo-like kinase 4. Science. 348:1155–1160. https:// 
doi .org/ 10 .1126/ science .aaa5111
Zhang, X., C. Yu, K. Wilson, H.Y. Zhang, S.D. Melton, X. Huo, D.H. Wang, R.M. 
Genta, S.J. Spechler, and R.F. Souza. 2010. Malignant transformation of 
non-neoplastic Barrett’s epithelial cells through well-defined genetic 
manipulations. PLoS One. 5:1–11. https:// doi .org/ 10 .1371/ journal .pone 
.0013093
Lopes et al. 
Centrosome amplification arises before neoplasia




Lopes et al., https:// doi .org/ 10 .1083/ jcb .201711191
Figure S1. Analysis of centriole numbers in patient samples. (A and B) Tissue samples of the normal ileum were stained for the cell membrane (E-cad-
herin), centrioles (GT335), and DNA (A) or for PCM (pericentrin), centrioles (GT335), and DNA (B). (A) Representative images show that the cell’s limits, de-
fined by E-cadherin staining, are easily distinguished using solely the GT335 background staining. Arrowheads indicate centrioles. Bar, 10 µm. 
(B) Representative images with enlargements of cells and centrioles in a single cell (arrowhead). Bars: (top) 50 µm; (bottom, main image) 10 µm; (bottom, 
inset) 1 µm. (C and D) The number of centrioles in each cell was analyzed in samples of the normal ileum, of the normal lining of the esophagus, and of the 
different stages of BE multistep tumorigenesis progression: metaplasia from biopsies of patients that have not progressed to this date (cohort 1) and areas 
of metaplasia, dysplasia, adenocarcinoma, and lymph node metastasis (met.) from cohorts 2 and 3. Samples were stained for PCM (pericentrin), centrioles 
(GT335), and DNA. (C) Quantification of cells with the indicated centriole number content for the tissue samples present in each case analyzed. n ≥ 200 cells/
tissue/patient. N, number of cases analyzed. Cells with more than four centrioles: *, P < 0.05; **, P < 0.01 (two-sample Wilcoxon rank-sum [Mann-Whitney]; 
independent samples; two sided; p-values were adjusted for multiple testing using the Benjamini and Hochberg method). (D) Number of centrioles per cell 
(individual circles) for the tissue samples present in each case analyzed. n = 200 cells/tissue/patient; number of cases was analyzed as in C. Individual data 
points are plotted over the box plots. (E) The number of centrioles in each cell was analyzed in metaplasia samples from biopsies of another 22 patients that 
have not progressed to this date. Samples were stained for centrioles (GT335) only and DNA. Quantification of cells with the indicated centriole number 
content. n ≥ 200 cells/patient. N, number of cases analyzed. Error bars show means ± SD.
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Figure S2. Analysis of p53 status in patient samples by IHC. (A and B) p53 expression was analyzed by IHC in tissue samples of the normal lining and in 
metaplasia and dysplasia samples from the same patient (cohort 2). (A) Representative images of p53 protein expression in the different tissue samples. DNA 
is shown in blue. Insets show 2× magnification of indicated areas. As WT p53 protein has a short half-life, it is only weakly detected in the nucleus of some 
proliferating cells (1) and not in differentiated areas (2). Altered p53 protein expression, indicative of p53 mutation, was considered when there was either a 
strong accumulation within the nucleus (scored as focal or diffuse if there were <10% or >10% of positive cells, respectively) caused by prolonged half-life of 
p53 mutants (p53 mutated) or absence of p53 staining (3) within a context of WT staining (metaplasia or native epithelium [4]) caused by p53 mutations, 
leading to truncation or epigenetic silencing, in which case p53 was not detected by IHC (p53 negative [absent]). Bars: (main images) 100 µm; (insets) 20 µm. 
(B) Histogram showing the summary of p53 status in metaplasia and dysplasia areas of each case analyzed.
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Figure S3. Centriole number and ploidy in cell lines. (A) Flow cytometry analysis of cells derived from the normal lining, metaplasia, and dysplasia. 
(B) Cells derived from the normal lining and from all stages of BE progression were stained for centrioles (centrin and GT335) and DNA. The number of cen-
trioles was analyzed in each individual mitotic cell (individual circles, n ≥ 60/cell line) of the indicated tissue of origin. Individual data points are plotted over 
the box plots. Met., metastasis. (C and D) Left: Metaplasia and dysplasia cells were stained for centrioles (centrin and CP110 in C, and centrin and GT335 in 
D) and DNA. Representative images with enlargements of centrioles (arrowheads) are shown. (C) Right: Quantification of mitotic cells with centriole ampli-
fication. n ≥ 50/cell line. (D) Right: Quantification of mononucleated interphase cells with centriole amplification. n ≥ 90/cell line. (E) Metaplasia cells were 
transfected with control (GL2) siRNA or siRNA against endogenous p53 (TP53). Top: Depletion of p53 was confirmed by WB. Bottom: Quantification of p53 
relative to the loading control (GAP DH) is shown; ratios were normalized to the untreated cells. Three independent experiments. (F and G) Metaplasia cells 
were transfected with control (GL2) or p53 (TP531) siRNA. (F) Top: Depletion of p53 was confirmed by WB. Bottom: Quantification of p53 relative to the 
loading control (GAP DH) is shown; ratios were normalized to the control. Two independent experiments. (G) Cells were stained for centrioles (centrin and 
GT335) and DNA. Quantification of mitotic cells with centriole amplification. n ≥ 60 cells/condition/experiment. Two independent experiments. (H and I) 
Centriole number was analyzed in metaplasia-derived cells containing pSUP ER-p53RNAi (shRNA TP532) or the empty pSUP ER vector (empty) as well as in 
metaplasia cells transfected with control (GL2) siRNA or siRNA against p53 with the same sequence against p53 (TP532) as the one used to generate the pSUP 
ER-p53RNAi plasmid. (H) Top: Depletion of p53 was confirmed by WB. Data are from one experiment. Bottom: Quantification of p53 relative to the loading 
control (GAP DH) is shown; ratios were normalized to the controls. (I) Cells were stained for centrioles (centrin and GT335) and DNA. Quantification of mitotic 
cells with centriole amplification. n ≥ 100 cells/condition. One experiment. (J and K) Normal lining cells were transfected with control (GL2) siRNA or two 
independent siRNAs against p53 (TP531 and TP532). (J) Top: Depletion of p53 was confirmed by WB. Bottom: Quantification of p53 relative to the loading 
control (GAP DH) is shown; ratios were normalized to the control. Three independent experiments. (K) Left: Cells were stained for centrioles (CP110 and 
GT335), microtubules (α-tubulin), and DNA. Representative images with enlargements of centrioles are shown. Right: Quantification of mitotic cells with 
centriole amplification. n ≥ 80/condition/experiment. Three independent experiments. (L and M) Metaplasia cells transfected with control (GL2) or p53 
(TP53) siRNA were stained for centrioles (centrin), PCM (γ-tubulin), and DNA (L) or for centrioles (centrin and GT335), microtubules (α-tubulin), and DNA (M). 
Representative images with enlargements of centrioles are shown. (N) Metaplasia cells were stained for p53, centrioles (centrin and CP110), and DNA. 
Dashed lines denote individual cell outlines given by the CP110/centrin background signal. Insets show centrioles (arrowheads) in p53-negative (1) and 
p53-positive (2) cells. (O and P) Metaplasia cells transfected with control (GL2) or p53 (TP53) siRNA were stained for centrioles (centrin and GT335) and DNA. 
(O) Dashed lines denote individual cell outlines given by the centrin/GT335 background signal. Insets show centrioles (arrowheads) in mononucleated (1) and 
multinucleated (2) cells. Bars: (main images) 10 µm; (insets) 1 µm. (P) Quantification of multinucleated interphase cells. Untreated metaplasia and normal 
lining cells were also analyzed. n ≥ 700 cells/condition/experiment. Three independent experiments. (K and P) **, P < 0.01 (ANO VA). (Q) Flow cytometry 
analysis of metaplasia cells transfected with control (GL2) siRNA or three independent siRNAs against p53 (endogenous p53, TP53; total p53, TP531 or TP532) 
and of metaplasia-derived cells containing pSUP ER-p53RNAi (shRNA TP532) or the empty pSUP ER vector (empty). (R and S) Metaplasia cells transfected 
with control (GL2) or p53 (TP53) siRNA were either treated with (S phase blocked and hydroxyurea [+HU]) or without hydroxyurea (DMSO, asynchronous, 
and −). (R) Top: Depletion of p53 was confirmed by WB. Bottom: Quantification of p53 relative to the loading control (GAP DH) is shown; ratios were normal-
ized to the control. Three independent experiments. Error bars show means ± SEM. (S) S phase blocking of cells upon hydroxyurea treatment was assessed 
by flow cytometry analysis.
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Table S1. Centriole number analysis in paraffin-embedded tissue
Tissue areas Centriole number per cell (min–max) Cells with centriole amplification
%
Normal lining – esophagus    
Cases 1–14 0–2 0.0
Normal lining – ileum    
Case 1–14 0–2 0.0
M DYS ADC LNM M DYS ADC LNM
Cohort 1
Case 1 1–4 - - - 0.0 - - -
Case 2 1–3 - - - 0.0 - - -
Case 3 1–4 - - - 0.0 - - -
Case 4 1–4 - - - 0.0 - - -
Case 5 1–4 - - - 0.0 - - -
Case 6 1–4 - - - 0.0 - - -
Cohort 2
Case 1 1–5 1–7 - - 1.5 8.5 - -
Case 2 1–5 1–5 - - 1.5 4.0 - -
Case 3 1–6 1–7 1–7 - 1.5 9.5 7.5 -
Case 4 1–72 1–76 1–6 - 3.5 9.0 5.0 -
Case 5 1–6 1–14 1–17 - 1.5 7.0 7.0 -
Cohort 3
Case 1 1–5 - 1–8 - 0.5 - 3.0 -
Case 2 1–6 - 1–13 1–22 1.0 - 5.5 13.0
Case 3 1–4 - 1–7 1–7 0.0 - 0.5 2.5
Case 4 1–4 - 1–8 - 0.0 - 2.0 -
Case 5 1–4 - 1–7 1–8 0.0 - 1.0 6.5
Case 6 1–5 - 1–7 - 0.5 - 1.5 -
Case 7 1–4 - 1–12 - 0.0 - 2.0 -
Case 8a 1–5 - 1–5 1–15 0.5 - 2.5 9.5
Case 9 1–4 - 1–10 1–19 0.0 - 0.5 13.0
Case 10 1–7 - 1–5 - 2.5 - 6.5 -
Case 11 1–4 - 1–8 1–7 0.0 - 1.5 5.0
Case 12 1–5 - 1–8 - 0.5 - 3.0 -
Case 13 1–5 - 1–6 - 1.0 - 3.0 -
Case 14 1–4 - 1–5 - 0.0 - 2.0 -
ADC, adenocarcinoma; DYS, dysplasia; LNM, lymph node metastasis; M, metaplasia. 
aThe cell line ESO51 used in this study was derived from the primary tumor of this case.
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Table S2. Analysis of TP53 status
Case/cell line Experiment Metaplasia Dysplasia
Coding Protein % Reads Coding Protein % Reads
Patient tissue samples – 
cohort 2




751A>C I251L 3.5 751A>C I251L 4.4
153_154insA Q52fs 24.2 153_154insA Q52fs 28.1
215C>G P72R 60.9 215C>G P72R 74.5
IHC WT Negative (absent)
Case 2 NGS n.d. n.d.
IHC WT Intensity: moderate
>10% cells mutated
Case 3 NGS 455delC P152fs 96.6
452C>A P151H 3.4
751A>C I251L 3.0 751A>C I251L 4.2
404G>T C135F 36.9 404G>T C135F 49.9
215C>G P72R 62.3 215C>G P72R 76.5
IHC Intensity: weak Intensity: strong
<10% cells mutated >10% cells mutated
Case 4 NGS 733G>A G245S 3.4
799C>T R267W 17.6
153_154insA Q52fs 22.9
751A>C I251L 3.3 751A>C I251L 6.0
215C>G P72R 62.3 215C>G P72R 76.5
IHC WT Intensity: strong
>10% cells mutated
Case 5 NGS 638G>A R213Q 3.3
524G>A R175H 6.6
153_154insA Q52fs 30.1
215C>G P72R 51.5 215C>G P72R 45.8
IHC WT Intensity: moderate
>10% cells mutated
Cell line
BAR-T NGS 215C>G P72R 98.3
*, nonsense mutation; fs, frameshift mutation; n.d., not determined due to insufficient amount of quality DNA; text in italics indicate known polymorphism 
in p53.
Table S3 is an attached Excel file showing cell line information and centriole analysis.
